Last reviewed · How we verify
ALK-positive metastatic NSCLC without brain metastases
Approved treatments
- Lorlatinib with chemotherapy 2 · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- ALK-positive metastatic NSCLC without brain metastases patent landscape — cliff calendar, originator estates, attackable patents
- ALK-positive metastatic NSCLC without brain metastases treatment landscape brief
- ALK-positive metastatic NSCLC without brain metastases treatment updates RSS
Frequently asked questions about ALK-positive metastatic NSCLC without brain metastases
What drugs treat ALK-positive metastatic NSCLC without brain metastases?
Tracked treatments include Lorlatinib with chemotherapy 2.
What is the treatment for ALK-positive metastatic NSCLC without brain metastases?
Standard treatment for ALK-positive metastatic NSCLC without brain metastases includes Lorlatinib with chemotherapy 2. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: ALK-positive metastatic NSCLC without brain metastases patent cliff · ALK-positive metastatic NSCLC without brain metastases CI report
- Treatment: Lorlatinib with chemotherapy 2 · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing